Quanterix Corp
Close on Oct 19, 2026
- Market cap
- $130.65M
- P/E (TTM)
- –
- Dividend yield
- –
Earnings
Next report expected Nov 9, 2026, after market close (estimated from past report dates)
| Quarter | Reported | Time | Revenue | EPS (GAAP) | EPS (adjusted) |
|---|---|---|---|---|---|
| Q2 FY2026 Ended Jun 30, 2026 | Aug 10, 2026 | Before market open | $32.90M | $-1.04 | – |
| Q1 FY2026 Ended Mar 31, 2026 | May 6, 2026 | After market close | $36.40M | – | – |
| Q4 FY2025 Ended Dec 31, 2025 | Mar 2, 2026 | After market close | $43.90M | $-0.49 | – |
| Q3 FY2025 Ended Sep 30, 2025 | Nov 10, 2025 | After market close | $40.20M | – | – |
| Q2 FY2025 Ended Jun 30, 2025 | Aug 7, 2025 | After market close | $24.50M | – | – |
| Q1 FY2025 Ended Mar 31, 2025 | May 12, 2025 | After market close | $30.30M | – | – |
| Q4 FY2024 Ended Dec 31, 2024 | Mar 17, 2025 | After market close | $35.20M | $-0.30 | – |
| Q3 FY2024 Ended Sep 30, 2024 | Nov 12, 2024 | After market close | $35.70M | – | – |
| Q2 FY2024 Ended Jun 30, 2024 | Aug 8, 2024 | After market close | – | – | – |
| Q1 FY2024 Ended Mar 31, 2024 | May 7, 2024 | After market close | – | – | – |
| Q4 FY2023 Ended Dec 31, 2023 | Feb 29, 2024 | After market close | – | – | – |
Company guidance
Outlook given with results on Aug 10, 2026, compared with the previous outlook
| Measure | Period | Guidance | vs. prior |
|---|---|---|---|
| non-GAAP gross marginsnon-GAAP | 2026 | 48% to 50% | Lowered |
| year-end cash balance | 2026 | $80.00M | New |
| revenues | 2026 | $142.00M to $148.00M | Lowered |
Figures and the sentence they come from are taken from the company's earnings release. Hover a measure to read the source sentence.
Press releases
Announcements Quanterix filed with the SEC
Quanterix Releases Financial Results for the Second Quarter of 2026
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
Q2 2026 Earnings Presentation Quanterix Corporation: (NASDAQ: QTRX) August 10th, 2026 Everett Cunningham, Chief Executive Officer Jason Faessler, Chief Financial Officer
Results of operations · Regulation FD disclosure · EX-99.2 to Form 8-K
Quanterix Names Jim Gute Chief Commercial Officer
Results of operations · Regulation FD disclosure · EX-99.3 to Form 8-K
Quanterix Announces Appointment of Jason Faessler
Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
Quanterix Announces Planned Transition of Chief Financial Officer
Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
Quanterix Releases Financial Results for the First Quarter of 2026
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
First Quarter 2026 Earnings Presentation May 6, 2026
Results of operations · Regulation FD disclosure · EX-99.2 to Form 8-K
Quanterix Releases Financial Results for the Fourth Quarter and Full Year 2025
Results of operations · EX-99.1 to Form 8-K
EX-99.2 to Form 8-K
Results of operations · EX-99.2 to Form 8-K
Quanterix Appoints Everett Cunningham as President and CEO Effective January 19, 2026
Results of operations · Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
Quanterix Announces Board and Leadership Changes to Support Next Stage of Growth
Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
Quanterix Releases Financial Results for the Third Quarter of 2025
Results of operations · EX-99.1 to Form 8-K
„ Third Quarter 2025 Earnings N o ve m ber 1 0 , 2 0 2 5
Results of operations · EX-99.2 to Form 8-K
Quanterix Releases Financial Results for the Second Quarter of 2025
Results of operations · Charter or bylaw amendment · Regulation FD disclosure · EX-99.1 to Form 8-K
EX-99.2 to Form 8-K
Results of operations · Charter or bylaw amendment · Regulation FD disclosure · EX-99.2 to Form 8-K
Quanterix Announces Cooperation Agreement with Kent Lake Capital
Material agreement · Regulation FD disclosure · EX-99.1 to Form 8-K
Quanterix Completes Acquisition of Akoya Biosciences, Creating the First Integrated Platform Capable of Measuring Biomarkers Across the Blood and Tissue Continuum
Acquisition or disposition completed · Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
Quanterix Releases Financial Results for the First Quarter of 2025
Results of operations · Exit or restructuring costs · EX-99.1 to Form 8-K
Quanterix and Akoya Biosciences Announce Amended
Material agreement · Regulation FD disclosure · EX-99.1 to Form 8-K
Amended Merger Agreement Synergistic Combination Delivering Compelling Strategic and Financial Benefits and Long - Term Value for Stockholders April 2025
Material agreement · Regulation FD disclosure · EX-99.2 to Form 8-K
Quanterix Releases Financial Results for the Fourth Quarter of 2024
Results of operations · EX-99.1 to Form 8-K
Quanterix Highlights Compelling Benefits of Akoya Biosciences Acquisition
Regulation FD disclosure · EX-99.1 to Form 8-K
Quanterix Provides Update on Financial Performance
Results of operations · EX-99.1 to Form 8-K
Today we announced our plans to acquire Akoya Biosciences. By combining leadership in ultra-sensitive biomarker detection in blood, Quanterix, with leadership in measuring biomarkers in tissue, Akoya Biosciences, we are building the toolset for this mission.
Regulation FD disclosure · EX-99.2 to Form 8-K
Subject: Important Update: Quanterix to Acquire Akoya
Regulation FD disclosure · EX-99.3 to Form 8-K
Quanterix to Acquire Akoya Biosciences, Creating the First Integrated Solution for Ultra-Sensitive Detection of Blood- and Tissue-Based Protein Biomarkers
Material agreement · Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
First Integrated Solution for Ultra- Sensitive Detection of Blood and Tissue Based Protein Biomarkers Uniquely positioned to speed up market development of new diagnostic testing solutions January 10, 2025
Material agreement · Results of operations · Regulation FD disclosure · EX-99.2 to Form 8-K
Quanterix Expands Capabilities with Strategic Acquisition of EMISSION
Material agreement · Regulation FD disclosure · EX-99.1 to Form 8-K
Quanterix Announces Receipt of Expected Notice from Nasdaq
Listing notice · Regulation FD disclosure · EX-99.1 to Form 8-K
Quanterix Releases Preliminary Financial Results for the Third Quarter of 2024
Results of operations · Prior financials no longer reliable · EX-99.1 to Form 8-K
Quanterix Releases Financial Results for the Second Quarter of 2024
Results of operations · EX-99.1 to Form 8-K
Quanterix Releases Financial Results for the First Quarter of 2024
Results of operations · Executive or director change · EX-99.1 to Form 8-K
Quanterix Releases Operating Results for Fourth Quarter and Full Year 2023
Results of operations · EX-99.1 to Form 8-K
Quanterix Reschedules Q4 and Full Year 2023 Earnings Conference Call; Reaffirms 2023 Guidance
Results of operations · EX-99.1 to Form 8-K
Create the tools enabling discovery and better health
Results of operations · EX-99.1 to Form 8-K
Quanterix Releases Operating Results for Third Quarter 2023
Results of operations · EX-99.1 to Form 8-K
Quanterix Releases Operating Results for Second Quarter 2023
Results of operations · EX-99.1 to Form 8-K
Quanterix Releases Operating Results for First Quarter 2023
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
We have made a modest positive adjustment to our full year
Results of operations · Regulation FD disclosure · EX-99.2 to Form 8-K